Latest Recruitment News

Close the Loop Limited reports stronger Q1 FY26 revenue and EBITDA, boosted by strategic asset sales and operational improvements, while navigating key board and CFO departures.

Tasmea Limited has announced the acquisition of WorkPac Group for up to A$60.7 million, significantly enhancing its workforce solutions capabilities and positioning the company for growth amid Australia's skilled labour shortages.

Tasmea Limited has entered a conditional agreement to acquire WorkPac Group for up to $60.7 million, aiming to enhance its workforce solutions and specialist trade services. The deal is expected to be accretive to earnings and strategically expand Tasmea’s footprint across Australia.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

Tryptamine Therapeutics has enrolled its second patient in a pioneering clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with first dosing scheduled for December and results expected early next year.

Meteoric Resources has successfully completed wet commissioning of its pilot plant in Brazil, marking a key milestone towards rare earth production at the Caldeira Project. First Mixed Rare Earth Carbonate output is expected early December, supporting ongoing feasibility studies and offtake partnerships.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Xamble Group reports a revenue rebound to A$1.7 million in Q3 2025 alongside narrowing EBITDA losses, reflecting early gains from its transformation strategy and technology investments.

Artrya Limited has expanded its SAPPHIRE clinical study with Ascension, one of the largest US non-profit health systems, joining as the fourth major participant. This move strengthens the study’s reach and advances the evaluation of Artrya’s AI-powered Salix platform for coronary artery disease detection.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.